Aeglea BioTherapeutics, Inc. announced that effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of the ocmpany, and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated. The Company intends to retain Mr. Kastenmayer as a consultant to assist in its strategic alternatives process. In connection with Mr. Goldberg's departure, the Board appointed Mr. Jonathan Alspaugh, the Company's Chief Financial Officer, as the Company's President and principal executive officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.16 USD | -2.83% | -8.66% | +50.88% |
15/05 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
13/05 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.88% | 1.33B | |
+8.83% | 115B | |
+9.87% | 105B | |
-12.92% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-15.95% | 16.01B | |
+1.20% | 14.14B | |
+18.05% | 10.71B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc. Announces Executive Changes